KLK3 and prostate carcinoma: In 2003, Guess and colleagues developed a Phase II clinical trial to investigate the tolerability and effect of PectaSol in patients with prostate cancer, showing that prostate cancer patients exhibited a serial increase in PSA after localized treatment (124).